Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td align="left"></td><td align="center">Detectable</td><td align="center">Suppressed</td><td align="center"><span style="width: 61.362499px;"><svg height="11.1" id="M26" style="vertical-align:-0.17555pt" version="1.1" viewbox="0 0 61.362499 11.1" width="61.362499" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,11.1)">
<g transform="translate(72,-63.12)">
<text transform="matrix(1,0,0,-1,-71.95,63.35)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑃</tspan>
<tspan style="font-size: 12.50px; " x="10.890113" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="22.930502" y="0">.</tspan>
<tspan style="font-size: 12.50px; " x="26.056252" y="0">0</tspan>
<tspan style="font-size: 12.50px; " x="32.307751" y="0">1</tspan>
<tspan style="font-size: 12.50px; " x="38.559254" y="0">5</tspan>
</text>
</g>
</g>
</svg></span></td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td align="left">3TC  naïve  (<svg height="11.1" id="M27" style="vertical-align:-0.17555pt" version="1.1" viewbox="0 0 35.099998 11.1" width="35.099998" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,11.1)">
<g transform="translate(72,-63.12)">
<text transform="matrix(1,0,0,-1,-71.95,63.35)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑛</tspan>
<tspan style="font-size: 12.50px; " x="9.6773224" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="21.71771" y="0">5</tspan>
</text>
</g>
</g>
</svg>)</td><td align="center">0 (0%)</td><td align="center">5 (100%)</td><td align="center">5 (100%)</td></tr><tr><td align="left">3TC experienced (<svg height="10.9125" id="M28" style="vertical-align:-0.17555pt" version="1.1" viewbox="0 0 42.912498 10.9125" width="42.912498" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.9125)">
<g transform="translate(72,-63.27)">
<text transform="matrix(1,0,0,-1,-71.95,63.5)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑛</tspan>
<tspan style="font-size: 12.50px; " x="9.6773224" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="21.71771" y="0">1</tspan>
<tspan style="font-size: 12.50px; " x="27.969212" y="0">3</tspan>
</text>
</g>
</g>
</svg>)</td><td align="center">9 (69%)</td><td align="center">4 (31%)</td><td align="center">13 (100%)</td></tr><tr><td align="center" colspan="4"><hr/></td></tr><tr><td align="left">Total</td><td align="center">9</td><td align="center">9</td><td align="center">18</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Patients with suppressed HBV VL 24 months after starting TDF/FTC.

International Scholarly Research Notices

tab3

Table 3

Table 3: Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients 